10 results on '"JUNLING YANG"'
Search Results
2. Fullerol rescues the light-induced retinal damage by modulating Müller glia cell fate
- Author
-
Zhe Cha, Zhiyuan Yin, Luodan A, Lingling Ge, Junling Yang, Xiaona Huang, Hui Gao, Xia Chen, Zhou Feng, Lingyue Mo, Juncai He, Shuang Zhu, Maoru Zhao, Zui Tao, Zhanjun Gu, and Haiwei Xu
- Subjects
Fullerol ,Light-induced retinal damage ,Müller glia ,De-differentiation ,Retina ,Medicine (General) ,R5-920 ,Biology (General) ,QH301-705.5 - Abstract
Excessive light exposure can damage photoreceptors and lead to blindness. Oxidative stress serves a key role in photo-induced retinal damage. Free radical scavengers have been proven to protect against photo-damaged retinal degeneration. Fullerol, a potent antioxidant, has the potential to protect against ultraviolet-B (UVB)-induced cornea injury by activating the endogenous stem cells. However, its effects on cell fate determination of Müller glia (MG) between gliosis and de-differentiation remain unclear. Therefore, we established a MG lineage-tracing mouse model of light-induced retinal damage to examine the therapeutic effects of fullerol. Fullerol exhibited superior protection against light-induced retinal injury compared to glutathione (GSH) and reduced oxidative stress levels, inhibited gliosis by suppressing the TGF-β pathway, and enhanced the de-differentiation of MG cells. RNA sequencing revealed that transcription candidate pathways, including Nrf2 and Wnt10a pathways, were involved in fullerol-induced neuroprotection. Fullerol-mediated transcriptional changes were validated by qPCR, Western blotting, and immunostaining using mouse retinas and human-derived Müller cell lines MIO-M1 cells, confirming that fullerol possibly modulated the Nrf2, Wnt10a, and TGF-β pathways in MG, which suppressed gliosis and promoted the de-differentiation of MG in light-induced retinal degeneration, indicating its potential in treating retinal diseases.
- Published
- 2023
- Full Text
- View/download PDF
3. Development of human retinal organoid models for bisphenol toxicity assessment
- Author
-
Minghui Li, Jing Gong, Lingling Ge, Hui Gao, Junling Yang, Cao Yang, Jiahui Kang, Yajie Fang, and Haiwei Xu
- Subjects
Bisphenols ,Human embryonic stem cells ,Retinal organoid ,Developmental retinal toxicity ,Transcriptomics analysis ,Environmental pollution ,TD172-193.5 ,Environmental sciences ,GE1-350 - Abstract
Bisphenols, including Bisphenol A (BPA), Tetrabromobisphenol A (TBBPA), and Tetrabromobisphenol S (TBBPS), have been widely applied in the production of polycarbonate plastics and epoxy resins and have been detected in the environment worldwide. The frequent detection of bisphenols in maternal and fetal samples has raised concerns about their toxic effects on human embryonic development, especially on the development of the central nervous system. However, the effect of bisphenols on human retinal development is still unknown. In this study, to evaluate the toxicity of bisphenols on early retinal development, human embryonic stem cells were induced to differentiate into retinal organoids that responded to BPA, TBBPA, and TBBPS, at human exposure relevant concentrations. The global gene expression of retinal organoids was analyzed by RNA sequencing (RNA-seq). A set of retinal development-related biological processes, including neuron differentiation, phototransduction, axon guidance, and retina layer formation, were identified in retinal organoids corresponding to different developmental stages. The RNA-seq data also showed that BPA, TBBPA, and TBBPS influenced retinal development by interfering with the Cytokine-cytokine receptor interaction pathway. HSPA6, HIF1A-AS3, CDC20B, IL19, OAS1, HSPA7, and RN7SK were dysregulated by these chemicals. Additionally, BPA, TBBPA, and TBBPS exhibited different toxic effects on neural retina development, with TBBPA appearing to exert more toxicity than BPA and TBBPS. Furthermore, three bisphenols exhibited different effects at different stages of neural retina development. The sensitivity of retinal development to bisphenols depends on their developmental stage. This study provides new insights into the deep dissection of retinotoxicity after prenatal bisphenol exposure.
- Published
- 2022
- Full Text
- View/download PDF
4. Fullerenol protects cornea from ultraviolet B exposure
- Author
-
Xia Chen, Junling Yang, Minghui Li, Shuang Zhu, Maoru Zhao, Cao Yang, Bo Liu, Hui Gao, Ao Lu, Lingling Ge, Lingyue Mo, Zhanjun Gu, and Haiwei Xu
- Subjects
Fullerenol ,Ultraviolet B ,Corneal protection ,Free radicals ,Medicine (General) ,R5-920 ,Biology (General) ,QH301-705.5 - Abstract
The eyes are highly susceptible to the oxidative stress induced by ultraviolet B (UVB, wavelength between 280 ∼ 320 nm), which could cause severe damage to the cornea. Fullerenols are effective antioxidants to alleviate UVB-induced injury, while their application for the eyes is still rare. In present study, we investigated the protective performance and mechanism of fullerenols on cornea under UVB radiation in vivo and in vitro. The synthesized fullerenols exhibited broad-spectrum free radical scavenging properties (applicable to both reactive oxygen species (ROS) and reactive nitrogen species (RNS)) and photo-stability. When compared with another widely used antioxidant glutathione (GSH), the administration of fullerenols markedly decreased the injured area, corneal edema, cell death, and increased the cell proliferation in UVB-induced rat cornea. The effects of fullerenols were confirmed in UVB-exposed human corneal epithelial cells (hCECs), where elevated cell viability and proliferation, decreased oxidative free radical production, repaired mitochondrial dysfunction and DNA lesions were observed. RNA sequencing (RNA-Seq) analysis demonstrated that fullerenol alleviated UVB-induced corneal injury through down-regulation of oxidative stress-related genes and up-regulation of proliferation-associated genes. Our results demonstrate the suitability of fullerenols as a potential exogenous treatment in ameliorating UVB-induced cornea damage.
- Published
- 2022
- Full Text
- View/download PDF
5. Evaluation of the influences of low dose polybrominated diphenyl ethers exposure on human early retinal development
- Author
-
Minghui Li, Yuxiao Zeng, Lingling Ge, Jing Gong, Chuanhuang Weng, Cao Yang, Junling Yang, Yajie Fang, Qiyou Li, Ting Zou, and Haiwei Xu
- Subjects
BDE-47 ,hESC-ROs ,Human retinal development ,Retinotoxicity ,Environmental sciences ,GE1-350 - Abstract
Increasing evidence in animal models has suggested that polybrominated diphenyl ethers (PBDEs), a class of brominated flame retardants, can cause retinotoxicity. However, data on the influence of PBDE treatment on human retinal development are scarce due to the lack of appropriate models. In the present study, we report the utilization of human embryonic stem cell-derived retinal organoids (hESC-ROs) for toxicity assessment of the most common PBDE congener (BDE-47) during the early stages of retinal development. Exposure to BDE-47 decreased the thickness and area of the neural retina (NR) of hESC-ROs in a dose- and time-dependent manner. Abnormal retinal cell distributions, disordered NR structures, and neural rosette-like structures were found on hESC-ROs after low-level BDE-47 exposure. Moreover, BDE-47 exposure decreased cell proliferation, promoted cell apoptosis, and caused abnormal differentiation. Transcriptomic analysis demonstrated that differentially expressed genes, caused by BDE-47, were enriched in extracellular matrix organization. Metabolomic studies of hESC-ROs revealed significant changes in the metabolism of purine and glutathione after BDE-47 exposure for five weeks. This study clarifies the retinotoxicity of low-level BDE-47 treatment and highlights the powerfulness of the hESC-RO model, deepening our understanding of BDE-47-driven human early retina developmental toxicity.
- Published
- 2022
- Full Text
- View/download PDF
6. High degree of pharmacokinetic compatibility exists between the five-herb medicine XueBiJing and antibiotics comedicated in sepsis care
- Author
-
Jian Li, Olajide E. Olaleye, Xuan Yu, Weiwei Jia, Junling Yang, Chuang Lu, Songqiao Liu, Jingjing Yu, Xiaona Duan, Yaya Wang, Kai Dong, Rongrong He, Chen Cheng, and Chuan Li
- Subjects
Therapeutics. Pharmacology ,RM1-950 - Abstract
Managing the dysregulated host response to infection remains a major challenge in sepsis care. Chinese treatment guideline recommends adding XueBiJing, a five-herb medicine, to antibiotic-based sepsis care. Although adding XueBiJing further reduced 28-day mortality via modulating the host response, pharmacokinetic herb–drug interaction is a widely recognized issue that needs to be studied. Building on our earlier systematic chemical and human pharmacokinetic investigations of XueBiJing, we evaluated the degree of pharmacokinetic compatibility for XueBiJing/antibiotic combination based on mechanistic evidence of interaction risk. Considering both XueBiJing‒antibiotic and antibiotic‒XueBiJing interaction potential, we integrated informatics-based approach with experimental approach and developed a compound pair-based method for data processing. To reflect clinical reality, we selected for study XueBiJing compounds bioavailable for drug interactions and 45 antibiotics commonly used in sepsis care in China. Based on the data of interacting with drug metabolizing enzymes and transporters, no XueBiJing compound could pair, as perpetrator, with the antibiotics. Although some antibiotics could, due to their inhibition of uridine 5′-diphosphoglucuronosyltransferase 2B15, organic anion transporters 1/2 and/or organic anion-transporting polypeptide 1B3, pair with senkyunolide I, tanshinol and salvianolic acid B, the potential interactions (resulting in increased exposure) are likely desirable due to these XueBiJing compounds' low baseline exposure levels. Inhibition of aldehyde dehydrogenase by 7 antibiotics probably results in undesirable reduction of exposure to protocatechuic acid from XueBiJing. Collectively, XueBiJing/antibiotic combination exhibited a high degree of pharmacokinetic compatibility at clinically relevant doses. The methodology developed can be applied to investigate other drug combinations. Key Words: XueBiJing, Antibiotic, Combination drug therapy, Sepsis, Pharmacokinetic compatibility, Herb‒drug interaction
- Published
- 2019
- Full Text
- View/download PDF
7. Relationship between blood eosinophil levels and COVID-19 mortality
- Author
-
Bingdi Yan, Junling Yang, Yan Xie, and Xiaolei Tang
- Subjects
SARS-CoV-2 ,COVID-19 ,Eosinophils ,Eosinopenia ,Mortality ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Objectives: A novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is causing the worldwide coronavirus disease 2019 (COVID-19) outbreak with high mortality. A unique finding among COVID-19 patients was a decline of eosinophil levels (eosinopenia). However, results from previous studies on the relationship between eosinopenia and disease severity were inconsistent. The objective of this study is to determine the relationship between eosinopenia and COVID-19 mortality as well as the clinical conditions that could potentially lead to mortality. Methods: One hundred ninety patients diagnosed as moderate, severe, or critical COVID-19 at hospital admission were enrolled. Data collected from patients’ medical records on the second day after hospital admission included medical histories, clinical symptoms, chest images of computed tomography (CT), laboratory examinations, and outcomes. Results: Eosinophil levels were significantly lower in patients with critical disease, when compared to those with moderate and severe diseases. After controlled for confounding factors, ie, age, gender, hypertension, coronary heart disease, diabetes, and chronic lung disease, a progressive decline of eosinophil levels was independently associated with mortality. Moreover, eosinophil levels significantly and positively correlated with platelet and D-dimer levels but significantly and inversely correlated with serum levels of urea, creatinine, aspartate aminotransferase, lactate dehydrogenase, and creatine kinase. Conclusions: Eosinopenia, if progressively worsening, indicates that COVID-19 patients may progress to critical disease and have a significantly higher chance of mortality. Additionally, eosinopenia correlates with biomarkers of coagulation disorder and those of tissue damage in kidney, liver, and other tissues.
- Published
- 2021
- Full Text
- View/download PDF
8. Prophylactic and Therapeutic Applications of Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer’s Disease
- Author
-
Stephanie Planque, Jinghong Kou, Sudhir Paul, Ken-ichiro Fukuchi, Junling Yang, Min Song, and Robert Lalonde
- Subjects
0301 basic medicine ,Immunoglobulin gene ,business.industry ,Morris water navigation task ,Inflammation ,Pharmacology ,Gene delivery ,medicine.disease ,Biochemistry of Alzheimer's disease ,Viral vector ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Cerebrospinal fluid ,medicine ,Cerebral amyloid angiopathy ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
The amyloid hypothesis has been the main theory to explain the etiology of Alzheimer’s disease (AD) and provided potentially preventive and therapeutic targets. Although Aβ-immunotherapy holds promise for AD, its vascular complications reduce the efficacy and safety. We produced an adeno-associated virus vector encoding Aβ-specific catalytic antibody, rAAV9-IgV L 5D3, and evaluated the prophylactic and therapeutic efficacy and safety of rAAV9-IgV L 5D3 brain delivery in an AD mouse model. One single injection of rAAV9-IgV L 5D3 into the right ventricle achieved widespread, high expression of IgV L 5D3 in the right hippocampus and cerebrospinal fluid but less expression in the left hemisphere. The prophylactic and therapeutic application of rAAV9-IgV L 5D3 reduced Aβ load in the right hippocampus. The therapeutic application improved long-term but not short-term memory on the Morris water maze without increasing cerebral amyloid angiopathy, microhemorrhage, and inflammation. Brain-targeted gene delivery of Aβ-specific catalytic antibody can be a safer and more effective approach for AD prevention and treatment than conventional anti-Aβ antibodies.
- Published
- 2018
- Full Text
- View/download PDF
9. List of Contributors
- Author
-
Christopher S. Ahuja, Marta M. Alonso, Victor L. Arvanian, Jacob I. Ayers, Paramita Chakrabarty, Rajeev K. Chaudhary, Zhiguo Chen, Leah Czerniewski, Dongsheng Duan, Michael G. Fehlings, Dahna M. Fong, Juan Fueyo, Ken-ichiro Fukuchi, Yandi Gao, Candelaria Gomez-Manzano, Renzhi Han, Zongchao Han, Shuanglin Hao, David M. Holtzman, Kyeung M. Joo, Jillian L. Joyce, Michael G. Kaplitt, Mohamad Khazaei, Kasun Kodippili, Jinghong Kou, Andrew W. Kraft, Sebastian Kügler, Robert Lalonde, Jin-Moo Lee, Young E. Lee, Mingjie Li, Roberta Marongiu, Naiara Martínez-Vélez, Kinjal A. Patel, Ana Patiño-García, Sudhir Paul, Hayk A. Petrosyan, Stephanie A. Planque, JeeHoon Roh, Zachary P. Rosenthal, Ipsita Roy, Ahad M. Siddiqui, B. Joy Snider, Min Song, Shuyan Wang, Matthew D. Wood, Angela Wu, Li Xu, Junling Yang, Deborah Young, and Yu Alex Zhang
- Published
- 2018
- Full Text
- View/download PDF
10. Intracranial IL-17A overexpression decreases cerebral amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer’s disease
- Author
-
Ken Ichiro Fukuchi, Robert Lalonde, Junling Yang, Jinghong Kou, University of Illinois College of Medicine, University of Illinois System, Stress, Immunité, Pathogènes (SIMPA), Université de Lorraine (UL), Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)
- Subjects
0301 basic medicine ,Hippocampus ,[SCCO]Cognitive science ,Behavioral Neuroscience ,Amyloid beta-Protein Precursor ,Mice ,0302 clinical medicine ,Cerebrospinal fluid ,ComputingMilieux_MISCELLANEOUS ,Aβ ,Microglia ,mouse behavior ,Interleukin-17 ,P3 peptide ,Brain ,Alzheimer's disease ,3. Good health ,Up-Regulation ,ERK signaling ,medicine.anatomical_structure ,Blood-Brain Barrier ,Mice, Inbred DBA ,Cytokines ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Cerebral amyloid angiopathy ,Interleukin 17 ,ATP Binding Cassette Transporter 1 ,Transcriptional Activation ,medicine.medical_specialty ,Immunology ,Biology ,Blood–brain barrier ,Article ,Proinflammatory cytokine ,03 medical and health sciences ,Alzheimer Disease ,Internal medicine ,endothelial ,medicine ,Animals ,Neuroinflammation ,Amyloid beta-Peptides ,Endocrine and Autonomic Systems ,[SCCO.NEUR]Cognitive science/Neuroscience ,ATP-binding cassette transporters ,medicine.disease ,Cerebral Amyloid Angiopathy ,Disease Models, Animal ,030104 developmental biology ,Endocrinology ,Th17 Cells ,interleukin 17 ,030217 neurology & neurosurgery - Abstract
International audience; Neuroinflammation is a pervasive feature of Alzheimer's disease (AD) and characterized by activated microglia, increased proinflammatory cytokines and/or infiltrating immune cells. T helper 17 (Th17) cells are found in AD brain parenchyma and interleukin-17A (IL-17A) is identified around deposits of aggregated amyloid β protein (Aβ). However, the role of IL-17A in AD pathogenesis remains elusive. We overexpressed IL-17A in an AD mouse model via recombinant adeno-associated virus serotype 5 (rAAV5)-mediated intracranial gene delivery. AD model mice subjected to injection of a vehicle (PBS) or rAAV5 carrying the lacZ gene served as controls. IL-17A did not exacerbate neuroinflammation in IL-17A-overexpressing mice. We found that IL-17A overexpression markedly improved glucose metabolism, decreased soluble Aβ levels in the hippocampus and cerebrospinal fluid, drastically reduced cerebral amyloid angiopathy, and modestly but significantly improved anxiety and learning deficits. Moreover, the ATP-binding cassette subfamily A member 1 (ABCA1), which can transport Aβ from the brain into the blood circulation, significantly increased in IL-17Aoverexpressing mice. In vitro treatment of brain endothelial bEnd.3 cells with IL-17A induced a dose-dependent increase in protein expression of ABCA1 through ERK activation. Our study suggests that IL-17A may decrease Aβ levels in the brain by upregulating ABCA1 in blood-brain barrier endothelial cells.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.